Cargando…

Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C

The expression of macrophage inhibitory factor-1 (MIC-1) increases in patients with chronic hepatitis C (CHC), but whether MIC-1 level and its polymorphism affect the antiviral efficacy of CHC has not yet been reported. The present study aimed to investigate the association between MIC-1 polymorphis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Songdao, Chen, Yao, Lou, Xiaoting, Ye, Xuanmei, Yang, Xunjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119258/ https://www.ncbi.nlm.nih.gov/pubmed/33604810 http://dx.doi.org/10.1007/s11010-021-04097-2

Ejemplares similares

Associations of content and gene polymorphism of macrophage inhibitory factor-1 and chronic hepatitis C virus infection
por: Yang, Xun-Jun, et al.
Publicado: (2020)

Elevated Expression of PDZD11 Is Associated With Poor Prognosis and Immune Infiltrates in Hepatocellular Carcinoma
por: Chen, Yao, et al.
Publicado: (2021)

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus
por: Wang, Ye, et al.
Publicado: (2015)

Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
por: Iliescu, Elena Laura, et al.
Publicado: (2020)

Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis
por: Alsayed, Mona Abdel Latif, et al.
Publicado: (2020)

Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C
por: Sherigar, Jagannath M., et al.
Publicado: (2017)

Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis
por: Kong, Yuan, et al.
Publicado: (2012)

Recent Advances in Antiviral Therapy for Chronic Hepatitis C
por: Tamori, Akihiro, et al.
Publicado: (2016)

Use of antiviral therapy in patients with chronic hepatitis C
por: Dragomiretskaya, Natalia, et al.
Publicado: (2015)

Correction: Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis
por: Alsayed, Mona Abdel Latif, et al.
Publicado: (2020)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

Genetic Polymorphism of CYP27B1-1260 as Associated With Impaired Fasting Glucose in Patients With Chronic Hepatitis C Undergoing Antiviral Therapy
por: Sun, Derong, et al.
Publicado: (2016)

Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience
por: Kaneko, Rena, et al.
Publicado: (2018)

Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people
por: De Santis, Adriano, et al.
Publicado: (2021)

Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation
por: Lin, Su, et al.
Publicado: (2017)

Liver cT(1) decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus
por: Jayaswal, Arjun N. A., et al.
Publicado: (2020)

Prediction of antiviral efficacy in patients with chronic hepatitis C by changes in forkhead box protein 3 levels
por: CHANG, JIA-BAO, et al.
Publicado: (2014)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Eczema craquelé associated with antiviral treatment for chronic hepatitis C
por: do Vale, Edla Polsinelli Bedin Mascarin, et al.
Publicado: (2017)

Liver-related effects of chronic hepatitis C antiviral treatment
por: Laursen, Tea L, et al.
Publicado: (2020)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
por: Hawsawi, Nahed Mohammed, et al.
Publicado: (2023)

Hemochromatosis Gene Polymorphism as a Predictor of Sustained Virological Response to Antiviral Treatment in Egyptian Chronic Hepatitis C Patients
por: I Mehrez, Mai, et al.
Publicado: (2017)

Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis
por: Sam, Napoleon Bellua, et al.
Publicado: (2019)

Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
por: Sahin, Ahmet, et al.
Publicado: (2023)

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies
por: Zhang, Zhiqing, et al.
Publicado: (2016)

Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients
por: Feng, Bo, et al.
Publicado: (2015)

Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation
por: Li, Guanghui, et al.
Publicado: (2020)

A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2
por: Yin, Peiqi, et al.
Publicado: (2017)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

The efficacy of biliary and serum macrophage inhibitory cytokine-1 for diagnosing biliary tract cancer
por: Sugimoto, Mitsuru, et al.
Publicado: (2017)

Genetic Polymorphisms of Vitamin D Pathway Predict Antiviral Treatment Outcome in Slow Responder Naïve Patients with Chronic Hepatitis C
por: Falleti, Edmondo, et al.
Publicado: (2013)

Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis
por: Ying, Sang-Yu, et al.
Publicado: (2021)

The Effect of Antiviral Therapy on Serum Cholesterol Levels in Chronic Hepatitis C
por: Jang, Eun Sun, et al.
Publicado: (2011)

Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
por: Batsaikhan, Batbold, et al.
Publicado: (2018)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7vb1jc2rrq43929vbv82bk00ma